Caveolin-1-containing extracellular vesicles transport adhesion proteins and promote malignancy in breast cancer cell lines

Papers of special note have been highlighted as: • of interest

References

• 1 Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591–602 (2005).
  Medline CASGoogle Scholar
• 2 Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 6, 449–458 (2006).
  Medline CASGoogle Scholar
• 3 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Medline CASGoogle Scholar
• 4 Nunez-Wehinger S, Ortiz RJ, Diaz N, Diaz J, Lobos-Gonzalez L, Ques AF. Caveolin-1 in cell migration and metastasis. Curr. Mol. Med. 14, 255–274 (2014).
  Medline CASGoogle Scholar
• 5 Ravid D, Maor S, Werner H, Liscovitch M. Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Adv. Enzyme Regul. 46, 163–175 (2006).
  Medline CASGoogle Scholar
• 6 Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563–572 (2002).
  Medline CASGoogle Scholar
• 7 Sugarbaker PH. Metastatic inefficiency: the scientific basis for resection of liver metastases from colorectal cancer. J. Surg. Oncol. Suppl. 3, 158–160 (1993).
  Medline CASGoogle Scholar
• 8 Weiss L. Metastatic inefficiency. Adv. Cancer Res. 54, 159–211 (1990).
  Medline CASGoogle Scholar
• 9 Diaz J, Mendoza P, Ortiz R et al. Rab5 is required in metastatic cancer cells for Caveolin-1-enhanced Rac1 activation, migration and invasion. J. Cell Sci. 127, 2401–2406 (2014).
  Medline CASGoogle Scholar
• 10 Lugini L, Matarrese P, Tinari A et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 66(7), 3629–3638 (2006).
  Medline CASGoogle Scholar
• 11 He M, Qin H, Poon TC et al. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs. Carcinogenesis 36, 1008–1018 (2015).
  Medline CASGoogle Scholar
• 12 Lazar I, Clement E, Ducoux-Petit M et al. Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines. Pigment Cell Melanoma Res. 28, 464–475 (2015). • The study shows that the specific protein composition of melanoma exosomes depends on the cell's aggressiveness (where Caveolin-1 was identified among these proteins) and suggests that exosomes influence the behavior of other tumor cells and their microenvironment.
  Medline CASGoogle Scholar
• 13 Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J. Cell Sci. 117, 5343–5351 (2004).
  Medline CASGoogle Scholar
• 14 Logozzi M, De Milito A, Lugini L et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE 4, e5219 (2009). • This group characterized and quantified exosomes by introducing a novel ELISA technique which was modified to detect CD63 and Caveolin-1 in conditioned media and plasma samples. The evidence provided in this study suggests that Caveolin-1 may serve as a cancer biomarker.
  MedlineGoogle Scholar
• 15 Cappello F, Logozzi M, Campanella C et al. Exosome levels in human body fluids: a tumor marker by themselves? Eur. J. Pharm. Sci. 96, 93–98 (2017).
  Medline CASGoogle Scholar
• 16 Zhao H, Achreja A, Iessi E et al. The key role of extracellular vesicles in the metastatic process. Biochim. Biophys. Acta 1869, 64–77 (2018).
  CASGoogle Scholar
• 17 Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 32, 623–642 (2013).
  Medline CASGoogle Scholar
• 18 Felicetti F, Parolini I, Bottero L et al. Caveolin-1 tumor-promoting role in human melanoma. Int. J. Cancer 125, 1514–1522 (2009).
  Medline CASGoogle Scholar
• 19 Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. (Berl.) 91, 431–437 (2013).
  Medline CASGoogle Scholar
• 20 Senetta R, Stella G, Pozzi E, Sturli N, Massi D, Cassoni P. Caveolin-1 as a promoter of tumor spreading: when, how, where and why. J. Cell Mol. Med. 17, 325–336 (2013).
  Medline CASGoogle Scholar
• 21 Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New technologies for analysis of extracellular vesicles. Chem. Rev. 118, 1917–1950 (2018).
  Medline CASGoogle Scholar
• 22 van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228 (2018).
  Medline CASGoogle Scholar
• 23 Zijlstra A, Di Vizio D. Size matters in nanoscale communication. Nat. Cell Biol. 20, 228–230 (2018).
  Medline CASGoogle Scholar
• 24 Harris DA, Patel SH, Gucek M, Hendrix A, Westbroek W, Taraska JW. Exosomes released from breast cancer carcinomas stimulate cell movement. PLoS ONE 10, e0117495 (2015). • Authors showed that exosomes from MDA-MB-231 metastatic human breast cancer cells are capable of promoting migration of non-metastatic MCF7 human breast cancer cells.
  MedlineGoogle Scholar
• 25 Bartz R, Zhou J, Hsieh JT, Ying Y, Li W, Liu P. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int. J. Cancer 122, 520–525 (2008).
  Medline CASGoogle Scholar
• 26 Andreu Z, Yanez-Mo M. Tetraspanins in extracellular vesicle formation and function. Front. Immunol. 5, 442 (2014).
  MedlineGoogle Scholar
• 27 Tahir SA, Yang G, Ebara S et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 61, 3882–3885 (2001).
  Medline CASGoogle Scholar
• 28 Tahir SA, Frolov A, Hayes TG et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin. Cancer Res. 12, 4872–4875 (2006).
  Medline CASGoogle Scholar
• 29 Urra H, Torres VA, Ortiz RJ et al. Caveolin-1-enhanced motility and focal adhesion turnover require tyrosine-14 but not accumulation to the rear in metastatic cancer cells. PLoS ONE 7, e33085 (2012). • Authors showed that the depletion of Caveolin-1 in MDA-MB-231 cells decreased migration, polarization and focal adhesion turnover in a sequence of events that involved phosphorylation of tyrosine 14 of this protein and Rac-1 activation.
  Medline CASGoogle Scholar
• 30 Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Chapter 3, Unit 3 22 doi: 10.1002/0471143030.cb0322s30. (2006).
  MedlineGoogle Scholar
• 31 Bendre V, Gautam M, Carr R, Smith J, Malloy A. Characterisation of nanoparticle size and concentration for toxicological studies. J. Biomed. Nanotechnol. 7, 195–196 (2011).
  Medline CASGoogle Scholar
• 32 Salomon C, Ryan J, Sobrevia L et al. Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis. PLoS ONE 8, e68451 (2013).
  Medline CASGoogle Scholar
• 33 Thomas PD, Kejariwal A, Campbell MJ et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res. 31, 334–341 (2003).
  Medline CASGoogle Scholar
• 34 Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. J. Hematol. Oncol. 8, 83 (2015).
  MedlineGoogle Scholar
• 35 Hoshino A, Costa-Silva B, Shen TL et al. Tumor exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015). • Authors reported the ability of MDA-MB-231 EVs of promoting metastasis to the lung and liver in an in vivo model depending on the presence of α1β1 and α1β3 integrins.
  Medline CASGoogle Scholar
• 36 Lobos-Gonzalez L, Aguilar L, Diaz J et al. E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment. Cell Melanoma Res. 26, 555–570 (2013).
  Medline CASGoogle Scholar
• 37 Fais S, O'Driscoll L, Borras FE et al. Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine. ACS Nano 10, 3886–3899 (2016).
  Medline CASGoogle Scholar
• 38 Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front. Genet. 4, 36 (2013).
  Medline CASGoogle Scholar
• 39 Coumans FAW, Brisson AR, Buzas EI et al. Methodological guidelines to study extracellular vesicles. Circ. Res. 120, 1632–1648 (2017).
  Medline CASGoogle Scholar
• 40 Jeppesen DK, Hvam ML, Primdahl-Bengtson B et al. Comparative analysis of discrete exosome fractions obtained by differential centrifugation. J. Extracell. Vesicles 3, 25011 (2014).
  MedlineGoogle Scholar
• 41 Mol EA, Goumans MJ, Doevendans PA, Sluijter JPG, Vader P. Higher functionality of extracellular vesicles isolated using size-exclusion chromatography compared to ultracentrifugation. Nanomedicine 13, 2061–2065 (2017).
  Medline CASGoogle Scholar
• 42 Keerthikumar S, Chisanga D, Ariyaratne D et al. ExoCarta: a web-based compendium of exosomal cargo. J. Mol. Biol. 428, 688–692 (2016).
  Medline CASGoogle Scholar
• 43 Willms E, Cabanas C, Mager I, Wood MJA, Vader P. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Front. Immunol. 9, 738 (2018).
  MedlineGoogle Scholar
• 44 Andreu Z, Yanez-Mo M. Tetraspanins in extracellular vesicle formation and function. Front. Immunol. 5, 442 (2014).
  MedlineGoogle Scholar
• 45 Lener T, Gimona M, Aigner L et al. Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. J. Extracell. Vesicles 4, 30087 (2015).
  MedlineGoogle Scholar
• 46 Cheng TY, Wu MS, Hua KT, Kuo ML, Lin MT. Cyr61/CTGF/Nov family proteins in gastric carcinogenesis. World J. Gastroenterol. 20, 1694–1700 (2014).
  Medline CASGoogle Scholar
• 47 Holbourn KP, Acharya KR, Perbal B. The CCN family of proteins: structure–function relationships. Trends Biochem. Sci. 33, 461–473 (2008).
  Medline CASGoogle Scholar
• 48 Huang YT, Lan Q, Lorusso G, Duffey N, Ruegg C. The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis. Oncotarget 8, 9200–9215 (2017). • Authors provide evidence indicating that Cyr61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and protection from anoikis during initial seeding to the lung.
  MedlineGoogle Scholar
• 49 Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21, 8178–8185 (2002).
  Medline CASGoogle Scholar
• 50 Jin Y, Kim HP, Cao J, Zhang M, Ifedigbo E, Choi AM. Caveolin-1 regulates the secretion and cytoprotection of Cyr61 in hyperoxic cell death. FASEB J. 23, 341–350 (2009). • Authors describe that CAV1/Cyr61 interaction via integrins represents a novel pathway of Cyr61 signaling involving CAV1-dependent processes which play a critical role in regulating cell processes such as hyperoxia-induced death.
  Medline CASGoogle Scholar
• 51 Onion D, Isherwood M, Shridhar N et al. Multicomponent analysis of the tumor microenvironment reveals low CD8 T cell number, low stromal caveolin-1 and high tenascin-C and their combination as significant prognostic markers in non-small cell lung cancer. Oncotarget 9, 1760–1771 (2018).
  MedlineGoogle Scholar
• 52 Adams M, Jones J, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res. 62, 3289–3297 (2002). • Authors showed that MDA-MB-231 cells produce Tenascin in contrast with tumor cells with lower invasive capacity such as MCF7 and T47-D. These results demonstrate for the first time that this protein is expressed in invasive breast carcinomas and may be used as a predictor for invasion.
  Medline CASGoogle Scholar
• 53 Oskarsson T, Acharyya S, Zhang XH et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 17, 867–874 (2011).
  Medline CASGoogle Scholar
• 54 Yoshida T, Ishihara A, Hirokawa Y, Kusakabe M, Sakakura T. Tenascin in breast cancer development – is epithelial tenascin a marker for poor prognosis? Cancer Lett. 90, 65–73 (1995).
  Medline CASGoogle Scholar
• 55 Bergenfelz C, Gaber A, Allaoui R et al. S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. Br. J. Cancer 113, 1234–1243 (2015).
  Medline CASGoogle Scholar
• 56 Miller P, Kidwell KM, Thomas D et al. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome. Breast Cancer Res. Treat. 166, 85–94 (2017).
  Medline CASGoogle Scholar
• 57 Zhang YL, Wang RC, Cheng K, Ring BZ, Su L. Roles of Rap1 signaling in tumor cell migration and invasion. Cancer Biol. Med. 14, 90–99 (2017).
  Medline CASGoogle Scholar
• 58 Rezaei M, Cao J, Friedrich K et al. The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor–endothelial cell interactions. Histochem. Cell Biol. 149, 15–30 (2018).
  Medline CASGoogle Scholar
• 59 Cancemi P, Di Cara G, Albanese N et al. Large-scale proteomic identification of S100 proteins in breast cancer tissues. BMC Cancer 10, 476 (2010). • Results obtained by authors suggest that a significant deregulation of S100 protein members is associated with breast cancer progression and might also act as potential prognostic factors for patient stratification.
  Medline CASGoogle Scholar
• 60 Palazzolo G, Albanese NN, Di Cara G, Gygax D, Vittorelli ML, Pucci-Minafra IDA. Proteomic analysis of exosome-like vesicles derived from breast cancer cells. Anticancer Res. 32(3), 847–860 (2012).
  Medline CASGoogle Scholar